Almaarefa University
The authoritative source for research information and outputs is Elsevier Scopus, with researcher profile verification from the Deanship of Scientific Research.

المخرجات

Research outputs

Articles, reviews, conference papers and book chapters, indexed by DOI and linked to University researchers.

176 output Results for «In silico»

ArticleOpen access20264citation· Semantic Scholar

Synthesis, biological evaluation and in silico studies of novel propargyl-tethered isatin hydrazones as monoamine oxidase inhibitors for Parkinson’s disease

Scientific Reports · vol. 16 (1)

Neurodegenerative disorders such as Parkinson’s disease are closely associated with dysregulated activity of monoamine oxidase-B (MAO-B), which leads to dopamine depletion and oxidative stress. Despite the availability of numerous monoamine oxidase (MAO) inhibitors on the market, their irreversibility and associated side effects necessitate the development of more effective and reversible MAO-B inhibitors. In this study, a series of twenty-one indole-based derivatives (PSH1 - PSH21) , collectively designated as PSH , was synthesised and evaluated for inhibitory activity against MAO isoforms. Most synthesised compounds showed higher inhibitory activity toward MAO-B than MAO-A, indicating selectivity for MAO-B. Among the PSH derivatives, PSH18 exhibited the most potent MAO-B inhibitory activity (IC 50 = 0.95 ± 0.02 µM), followed by PSH6 ( IC 50 = 1.79 ± 0.40 µM) and PSH2 (IC 50 = 1.96 ± 0.08 µM). Compound PSH18 showed the highest selectivity index value of 42.11, followed by PSH6 (22.35) and PSH2 (20.41). Additionally, PSH18 was confirmed to be a competitive and reversible inhibitor of MAO-B with an inhibition constant value of 0.89 ± 0.035 µM. Notably, PSH18 exhibited good permeability across the blood–brain barrier in parallel artificial membrane permeability assay experiments, along with acceptable absorption, distribution, metabolism, excretion, and toxicity parameters predicted through in silico modelling, suggesting its potential as a central nervous system-targeted molecule. Molecular docking and a 200 ns molecular dynamics simulation demonstrated stable binding of the ligand to the MAO-B active-site pocket, driven by hydrophobic and π–π stacking interactions with key amino acid residues lining the aromatic cage. Moreover, the calculated binding energy indicated strong ligand–protein interactions. Overall, these results indicate that the PSH scaffold could serve as a promising lead structure for the development of potent and selective MAO-B inhibitors. These compounds may have therapeutic potential for the treatment of neurodegenerative diseases.

monoamine oxidase B inhibitorsParkinson's diseaseblood-brain barrier permeabilityADME prediction
ArticleClosed20263citation· Semantic Scholar

Integrative in silico-in vivo modeling identifies apigenin modulation of TGF-β1/SMAD2 in methotrexate-induced cardiotoxicity

Toxicology Mechanisms and Methods · vol. 36 (3) · 412-431

Methotrexate (METX) is a widely used chemotherapeutic and immunosuppressive agent, frequently employed as a first-line treatment for various malignancies and autoimmune disorders. Despite its clinical efficacy, METX is known to induce cardiotoxicity primarily through mechanisms involving oxidative stress, inflammation, and apoptosis. Apigenin (API), a natural dietary flavonoid, exhibits potent antioxidant and anti-inflammatory properties. The current study evaluated the protective effects of API against METX-induced cardiotoxicity in mice, focusing on the modulation of transforming growth factor-β (TGF-β)/(SMAD2) signaling. Molecular docking was done to investigate the possible inhibition of TGF-β by API and bioinformatic tools were utilized to investigate the correlation between the target proteins. Male Swiss albino mice were randomly distributed to four groups: Group I: a saline group, Group II: a METX control group (20 mg/kg, per week), Group III: METX + API (40 mg/kg, per day) and Group IV: METX + API (80 mg/kg, per day, via oral gavage); the study continued for three weeks. Our findings suggest that API administration significantly mitigated METX cardiotoxicity and serum CK-MB, likely through attenuation of the inflammatory cytokines (NF-κB, IL-1β, TNF-α, and IL-6) and suppression of cardiac TGF-β/SMAD2 signaling. The congruence between bioinformatics and experimental validation findings strongly highlighted API as a promising therapeutic candidate for alleviating METX cardiotoxicity. While the current data reveals key underlying molecular mechanisms for API′s cardioprotective effect, further comprehensive studies across diverse cardiotoxicity models are essential to fully elucidate cardioprotective effect of API.

apigeninTGF-β/Smad2 signalingflavonoidscardioprotection
ArticleOpen (repository)20262citation· Semantic Scholar

Chemical Profiling, Pharmacological Activities, and Toxicity Assessment of Juniperus phoenicea sp. turbinata L. Extract: Integrated In Vitro, In Vivo, and In Silico Insights

Food Science & Nutrition · vol. 14 (5) · e71878-e71878

ABSTRACT Juniperus phoenicea ssp. Turbinata L. ( J. phoenicea ssp. Turbinata) has long been used in traditional medicine to treat a variety of ailments. This study aimed to investigate the pharmacological potential and to characterize the phytochemical composition of the hydroethanolic leaf (JPEF) and fruit (JPEG) extracts. Liquid Chromatography Tandem Mass Spectrometry (LC–MS/MS) analysis revealed that both JPEF and JPEG contained high levels of phenolic compounds, with ferulic acid identified as the dominant constituent. The biological evaluation began with acute toxicity tests in rodents, which indicated that JPEF and JPEG extracts were well tolerated at the doses administered, with no significant adverse effects observed. The extracts exhibited strong anti‐inflammatory activity (94.23% for JPEF; 83.24% for JPEG), comparable to that of diclofenac (97.02%), as well as a notable analgesic effect (75% and 70.62%), compared to tramadol (87.01%). Significant antioxidant activity was observed (DPPH IC 50 : 70.2 and 90.76 μg/mL), accompanied by antimicrobial activity (bacterial inhibition zones: 11.44–20.36 mm; fungal: 13.59–20.38 mm). Molecular docking revealed a stable interaction between the compounds and several enzymatic targets. These results confirm the potential of J. phoenicea ssp. turbinata as a promising source of therapeutic agents.

leaf extractfruit extractphytochemical profilingferulic acid
ArticleOpen access20262citation· Semantic Scholar

Identification of Apixaban as a Potential Inhibitor of the SARS‐CoV‐2 Main Protease: A Multistage Computational Study

Journal of Chemistry · vol. 2026 (1)

The SARS‐CoV‐2 main protease (M pro ) remains a critical therapeutic target for COVID‐19 intervention. In this study, we employed a comprehensive in silico repurposing strategy to identify FDA‐approved drugs with potential inhibitory activity against M pro . An initial molecular fingerprint screening of 3009 FDA‐approved compounds, based on similarity to the cocrystallized inhibitor X77, yielded 150 similar candidates. Subsequent structural similarity filtering reduced the list to 30 compounds, which were subjected to molecular docking. Apixaban demonstrated strong binding affinity and favorable interaction patterns within the M pro active site and was selected for further investigation. A 100‐ns molecular dynamics simulation comparing the apo and holo forms confirmed the structural stability of the M pro –apixaban complex. Apixaban remained stably positioned within the binding pocket, while reduced RMSF values in key active‐site residues indicated apixaban‐induced stabilization. Molecular mechanics–generalized Born surface area (MM‐GBSA) analysis estimated a binding free energy of −22.19 kcal/mol, with van der Waals interactions contributing predominantly to complex stability. Per‐residue decomposition highlighted significant contributions from Met165 and Gln189. Protein–ligand interaction fingerprinting (ProLIF) and protein–ligand interaction profiler (PLIP) analyses revealed persistent hydrogen bonds and hydrophobic contacts involving Asn142, Cys145, Gln189, Thr190, Gln192, and Arg188. Principal component analysis of trajectories (PCAT) demonstrated apixaban‐induced modulation of collective motions and partial closure of the binding pocket. Importantly, this study provides detailed atomistic insights into the potential interaction of apixaban with M pro . Together, these findings offer a plausible molecular rationale for its inhibitory activity and support further experimental and pharmacological evaluation of apixaban as a potential therapeutic candidate targeting SARS‐CoV‐2 M pro .

apixabanmain proteaseCOVID-19 pandemicdrug repurposing
ArticleClosed20261citation· Semantic Scholar

Cytoprotective Effects of Fagonia arabica against Oxidative and Neurotoxic Stress: GC-MS-guided In Vitro and In Silico Evaluation in SK-N-SH Cells

Current Bioactive Compounds · vol. 22

Introduction: Neurodegenerative diseases present major challenges in biomedical research, and identifying natural sources with potential cytoprotective effects remains an important exploratory goal. This study investigates the cytoprotective properties of Fagonia arabica in human neuroblastoma (SK‑N‑SH) cells exposed to oxidative and neurotoxic stressors. Methods: he dried plant material was subjected to a sequential solvent extraction method. The antioxidant and anti-inflammatory activity was assessed by standard procedures. Cytotoxicity was assessed in L929 fibroblasts, and in vitro neuroprotective effects were examined in SK‑N‑SH neuroblastoma cells exposed to trimethyltin (TMT). The GCMS analysis identified the phytocompounds, and an in silico study was performed using molecular docking against targeted proteins. Results: The phytochemical analysis identified phytochemicals like flavonoids, alkaloids, and phenols. In silico analysis indicated that several detected phytochemicals showed notable binding affinity toward targets associated with oxidative stress and inflammation. The extract exhibited anti-inflammatory effects in protein denaturation (IC50 141.88 µg/mL) and COX-2 inhibition assays (IC50 53.65 µg/mL), along with antioxidant activity via DPPH scavenging (IC50 138.14 µg/mL). Cytotoxicity testing demonstrated low toxicity in L929 cells (IC50 = 162.43 µg/mL). In the TMT‑injury model, the extract improved SK‑N‑SH cell viability (86.52% at 50 µg/mL), indicating potential cytoprotective activity under oxidative stress conditions. Results: The phytochemical analysis identified phytochemicals like flavonoids, alkaloids, and phenols. In silico analysis indicated that several detected phytochemicals showed notable binding affinity toward targets associated with oxidative stress and inflammation. The extract exhibited anti-inflammatory effects in protein denaturation (IC50 141.88 µg/mL) and COX-2 inhibition assays (IC50 53.65 µg/mL), along with antioxidant activity via DPPH scavenging (IC50 138.14 µg/mL). Cytotoxicity testing demonstrated low toxicity in L929 cells (IC50 = 162.43 µg/mL). In the TMT‑injury model, the extract improved SK‑N‑SH cell viability (86.52% at 50 µg/mL), indicating potential cytoprotective activity under oxidative stress conditions. Discussion: The biological activities of the extract are likely due to its phytochemical constituents, particularly flavonoids and phenolic compounds. The in silico predictions supported the experimental findings of anti-inflammatory and antioxidant activities. The extract also showed low cytotoxicity and demonstrated cytoprotective effects under oxidative stress conditions, suggesting potential therapeutic value, warranting further investigation into its mechanisms and pharmacological applications. Conclusion: Fagonia arabica demonstrated antioxidant, anti-inflammatory, and preliminary neuroprotective effects at the cellular level. While these findings support the plant’s potential as a source of bioactive compounds with neuroprotective potential, the study does not directly model the complex pathology of Alzheimer’s disease. Further investigations using disease-relevant models are required to clarify its therapeutic relevance

Fagonia arabicaneuroprotectionoxidative stressneurotoxicity
ArticleOpen access2026

In silico assessment of catenulopyrizomicin A and B as potential inhibitors of HCV NS3/4A protease

Discover Applied Sciences

The hepatitis C virus (HCV) has no vaccine, and available therapies are linked to adverse outcomes, high costs and emergence of resistance. A previous study have identified catenulopyrizomicin A and B as bioactive compounds from natural products with reported antiviral properties, warranting further evaluation against the HCV NS3/4A protease using non-in silico methods. The aim of this study was to evaluate the anti-HCV potentials of catenulopyrizomicins A and B against 5EQS, a genotype 1a/3a chimeric HCV NS3/4A protease of HCV using in silico approaches. In this study, the anti-HCV potential of catenulopyrizomicin A and B was evaluated using in silico approaches (molecular docking, simulation, ADMET profiling, and DFT) with ribavirin as a control, and 5EQS as the target protein (NS3/4A). Docking scores for the ligands were − 5.8, − 5.8, and − 6.1 kcal/mol, respectively, for catenulopyrizomicin B, ribavirin, and catenulopyrizomicin A. Two dimensional (2D) visualisation of the formed complexes revealed the dominance of Van der Waals forces and polar interactions between the ligands and the target protein. Molecular dynamics simulations revealed variations in RMSD and RMSF that indicated that the formed stable complexes with values that remained below 2.0 Å throughout most of the simulation runs, indicating stability. Ligand-protein contact analysis revealed the presence of conserved residues, including Gln1041, Thr1042, His1057, Arg1109, Leu1132, Leu1135, Lys1136, and Cys1159 across the test ligands, suggesting that they may be important in ligand recognition and foramtion of stable interactions. ADMET properties revealed that catenulopyrizomicin A and B had better intestinal absorption rates (36.41% and 36.28%) than ribavirin (30.95%), as well as good distribution, as revealed by their better VDss values (− 0.53 to − 0.61 for catenulopyrizomicin A and B) compared to ribavirin which was − 0.22. The DFT results showed that catenulopyrizomicin A and B were more reactive and nucleophilic than ribavirin. The findings suggest that catenulopyrizomicin A and B may serve as potential lead compounds for anti-HCV drug development. However, further in vitro and in vivo studies are required to validate their antiviral activity and pharmacological properties.

hepatitis C virusNS3/4A proteaseprotease inhibitorsmolecular docking
ArticleOpen (repository)2026

Integrated in vitro and in silico evaluations of novel benzanilide derivatives as anticancer agents

Future Medicinal Chemistry · vol. 18 (19) · 2645-2662

Aims This study aimed to design, synthesize, and evaluate novel benzanilide derivatives as potential anticancer agents targeting VEGFR-2-mediated tumor angiogenesis.Materials and methods Eight benzanilide derivatives (7a-e, 9a-b, and 11) were synthesized and structurally confirmed using spectroscopic methods. The compounds were evaluated via molecular docking, in silico ADMET profiling, in vitro cytotoxicity against MCF-7, MDA-MB-231, HepG-2, and HCT-116 cancer cell lines, and selectivity assessment using WI-38 and WISH normal cell lines. VEGFR-2 enzyme inhibition was also determined for the most active compound.Results Compound 11 exhibited the highest cytotoxic activity with IC50 values of 6.08, 5.76, 7.94, and 4.64 µM against MCF-7, MDA-MB-231, HepG-2, and HCT-116, respectively, comparable to sorafenib. It showed potent VEGFR-2 inhibition (IC50 = 0.414 µM) superior to sorafenib (0.809 µM). Mechanistic studies indicated activation of apoptosis via upregulation of Bax, Caspase-3, and Caspase-8 and downregulation of Bcl-2. ADMET results revealed favorable pharmacokinetic properties and acceptable safety profiles.Conclusions Compound 11 represents a promising VEGFR-2 inhibitor with potent anticancer activity and favorable drug-like properties, warranting further optimization and development.

VEGFR-2 inhibitorsanticancer agentstumor angiogenesiscytotoxicity
ArticleOpen (repository)2026

New Chromene Derivatives as Promising VEGFR‐2 Inhibitors: Experimental Cytotoxicity and Comprehensive Computational Characterization

Archiv der Pharmazie · vol. 359 (9) · e70328-e70328

ABSTRACT A new series of chromene derivatives ( 12–19 ) was rationally designed as potential inhibitors of vascular endothelial growth factor receptor‐2 (VEGFR‐2) by integrating essential pharmacophoric and structural features. The target compounds were synthesized and structurally confirmed using spectroscopic techniques. Their in vitro antiproliferative activities were evaluated against a panel of human cancer cell lines (MCF‐7, MDA‐MB‐231, HepG‐2, and HCT‐116) alongside normal human cells (WI‐38 and WISH), in addition to a VEGFR‐2 enzyme inhibition assay. Among the synthesized derivatives, compound 17 emerged as the most potent candidate, displaying low micromolar IC 50 values across all tested cancer cell lines and superior VEGFR‐2 inhibitory activity (IC 50 = 0.518 µM) compared with the reference drug sorafenib (IC 50 = 0.809 µM). Mechanistic investigations revealed that compound 17 induced pronounced cell cycle arrest and triggered apoptosis, as demonstrated by Annexin V–FITC/PI flow cytometric analysis. Computationally, Density Functional Theory (DFT) calculations demonstrated favorable electronic properties for compound 17, supporting effective ligand–receptor interactions. Molecular docking and 100‐ns molecular dynamics (MD) simulations, complemented by MM‐GBSA binding free energy calculations, Protein–Ligand Interaction Fingerprinting (Pro‐LIF), Principal Component Analysis (PCA‐T), and Free Energy Landscape (FEL) analyses, confirmed the stability and favorable binding energetics of compound 17 within the VEGFR‐2 active site. Furthermore, in silico ADME–Tox profiling predicted acceptable pharmacokinetic behavior and a favorable safety profile. Collectively, these experimental and computational findings identify compound 17 as a promising and mechanistically well‐characterized VEGFR‐2 inhibitor, warranting further in vivo investigation.

chromene derivativesVEGFR-2 inhibitorsantiproliferative activitycancer cell lines
ArticleClosed2026

Integrated In Silico and In Vitro Discovery of a VEGFR-2-Targeted Anticancer Benzanilide Lead

Journal of Computational Biophysics and Chemistry · 1-20

The development of selective vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors remains a promising strategy for anticancer therapy targeting tumor angiogenesis. In the study at hand, a novel benzanilide-based derivative, ACEB-Cl, was rationally designed by assimilating fundamental pharmacophoric characteristics essential for VEGFR-2 inhibition. ACEB-Cl was evaluated using a comprehensive approach that combined computational modeling, synthesis, and in vitro biological assessment. Density functional theory (DFT) calculations revealed a favorable electronic profile, with distinct nucleophilic and electrophilic regions that could support potential interactions within the VEGFR-2 binding pocket. Docking and molecular dynamics (MD) simulations suggested stable binding of ACEB-Cl within the ATP-binding pocket, supported by strong hydrophobic interactions and favorable binding free energy ([Formula: see text] kcal/mol). Following synthesis, ACEB-Cl confirmed potent anti-VEGFR-2 activity in an ELISA-based assay (IC[Formula: see text]M), showing higher potency than sorafenib. Western blot analysis further confirmed significant downregulation of phosphorylated VEGFR-2 in MDA-MB-231 cells. In vitro cytotoxicity studies revealed selective anticancer activity, with reduced toxicity toward normal Vero cells and favorable selectivity indices. Mechanistically, ACEB-Cl triggered G0/G1 phase arrest and significantly increased apoptotic cell death, highlighting its ability to suppress cancer cell proliferation. Additionally, ADMET and toxicity estimations indicated a balanced pharmacokinetic and safety profile, with improved solubility, acceptable absorption, and reduced toxicity risks compared to sorafenib. Overall, this integrated study pinpointed ACEB-Cl as a promising VEGFR-2-targeted anticancer lead compound with strong inhibitory potency and a clearly defined mechanism of action, supporting its progression for further improvement.

VEGFR-2 inhibitorsbenzanilidestumor angiogenesisanticancer drug discovery
ArticleOpen access2026

Solvent-driven modulation of phenolic composition and biofunctional activities of three Mentha aquatica formulations: integrated in vitro and in silico insights

Bioresources and Bioprocessing · vol. 13 (1)

The goal of this work was to examine the effect of different solvents (Water, EtOH 70%, and acetone) on the phenolic composition, antioxidant, and antibacterial capacity of Moroccan Mentha aquatica L. leaf extract. To this end, HPLC-ESI-FULL-MS was used to characterize the extracts, while the Folin-Ciocalteu and aluminum trichloride techniques were used to evaluate the total phenolic and flavonoid contents. To assess the antibacterial capacity, the microdilution technique was performed to calculate the minimal inhibition concentration (MIC), and minimal bactericidal concentration (MBC). Phytochemical profiling revealed that the extracts were rich in bioactive constituents, particularly ferulic acid derivative, caffeoyl-protocatechuic acid derivative, quercetin, and diosmetin 7-O-beta-D-glucuronide. The hydroethanolic extract contained the highest levels of total phenolic (62.2 ± 1.2 mg GAE/g DW) and flavonoid (29.15 ± 0.09 mg QE/g DW) contents, exceeding those of the acetonic extract (22.2 ± 0.6 and 10.17 ± 0.07 mg GAE/g DW, respectively) and the water extract (22.4 ± 0.6 and 10.9 ± 0.6 mg QE/g DW, respectively). This extract also showed the strongest antioxidant effect, recording an IC50 of 0.060 ± 0.001 mg/mL in the DPPH assay, and an EC50 of 80 µg/mL in the RP test. In addition, it shows a great total antioxidant capacity, reaching 75.1 ± 2.0 mg EAA/g DW when compared to water and acetonic extracts (28.5 ± 1.4 and 21.1 ± 0.1 mg EAA/g DW, respectively). The antibacterial potential ranges from 0.78 ± 0.05 mg/mL to 12.6 mg/mL. In-silico prediction highlighted diosmetin 7-O-beta-D-glucuronide, quercetin, and equisetumpyrone as the key contributors to antioxidant capacity, while quercetin, 2,3,8-Tri-O-methylellagic acid, and diosmetin 7-O-beta-D-glucuronide were involved in antibacterial activity.

Mentha aquaticasolvent extractionphenolic compositionflavonoids
ArticleClosed2026

Development of a Novel Benzanilide Derivative Targeting VEGFR-2: Computational Modeling and In Vitro Anticancer Validation

Journal of Computational Biophysics and Chemistry · 1-20

The pursuit of selective vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors continues to be a key approach in anticancer drug discovery. In this context, a new benzanilide-based derivative, Z-CMPBC, was designed following essential VEGFR-2 pharmacophoric requirements and investigated through combined computational and biological approaches. Density functional theory (DFT) calculations at the B3LYP/6-31[Formula: see text]G(d, p) level indicated favorable electronic characteristics, including balanced chemical hardness and pronounced electrophilicity, suggesting a strong propensity for interaction within kinase active sites. Molecular docking, supported by 200 ns molecular dynamics simulations, demonstrated stable accommodation of the compound within the VEGFR-2 binding pocket. Binding free energy calculations using the MM-GBSA method revealed a significant interaction profile ([Formula: see text] kcal/mol), mainly governed by van der Waals forces and persistent hydrophobic interactions with critical residues. Biological assessment confirmed potent VEGFR-2 inhibition, with an IC[Formula: see text] value of [Formula: see text]M, closely comparable to sorafenib ([Formula: see text]M). Western blot analysis further verified a reduction in phosphorylated VEGFR-2 (pY1054/Y1059) levels in MCF-7 cells, supporting effective intracellular kinase inhibition. Additionally, Z-CMPBC exhibited pronounced cytotoxicity, particularly against MCF-7 breast cancer cells (IC[Formula: see text]M), along with a high selectivity index ([Formula: see text]) relative to normal Vero cells. Flow cytometry analysis demonstrated induction of G0/G1 phase arrest, accompanied by enhanced apoptotic activity (34.05%) compared to untreated cells. In silico ADMET and toxicity predictions suggested acceptable pharmacokinetic behavior and safety characteristics. Overall, these findings highlight Z-CMPBC as a promising VEGFR-2 inhibitor with potential for further development as an anticancer agent.

VEGFR-2 inhibitorsanticancer drug discoverykinase inhibitorsMCF-7 cells